LGVN News and Press, Longeveron Inc. From 10/13/23

MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...

2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a defin...

2023-10-12 08:24:41 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript Longeveron falls after mid-stage data for Alzheimer’s candidate Longeveron announces pricing for ri...

2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...

MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...

2023-10-10 08:23:35 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript Longeveron falls after mid-stage data for Alzheimer’s candidate Longeveron announces pricing for ri...

2023-10-09 10:00:00 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid For further details see: Bioline Rx, Clever Leaves among healthcare movers

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

2023-10-06 08:53:38 ET OMNIQ ( OMQS ) -44% announces pricing of public offering. Wheeler Real Estate Investment Trust  ( WHLR ) -21% . ShiftPixy  ( PIXY ) -19% . Nanobiotix  ( NBTX ) -15% . Aehr Test ( AEHR ) -11% . ...